WO2001080824A3 - Dual mechanism timed release dosage forms for low dose drugs - Google Patents

Dual mechanism timed release dosage forms for low dose drugs Download PDF

Info

Publication number
WO2001080824A3
WO2001080824A3 PCT/US2001/010175 US0110175W WO0180824A3 WO 2001080824 A3 WO2001080824 A3 WO 2001080824A3 US 0110175 W US0110175 W US 0110175W WO 0180824 A3 WO0180824 A3 WO 0180824A3
Authority
WO
WIPO (PCT)
Prior art keywords
release
release profiles
membrane
dual mechanism
dosage forms
Prior art date
Application number
PCT/US2001/010175
Other languages
French (fr)
Other versions
WO2001080824A2 (en
Inventor
James M Clevenger
Alfio B Gallo
Der-Yang Lee
Gopi M Venkatesh
Krishna S Vishnupad
Original Assignee
Eurand America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand America Inc filed Critical Eurand America Inc
Priority to AU2001247887A priority Critical patent/AU2001247887A1/en
Publication of WO2001080824A2 publication Critical patent/WO2001080824A2/en
Publication of WO2001080824A3 publication Critical patent/WO2001080824A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

In accordance with the present invention, the release rate of a bioactive material from a hydrophilic polymer matrix core is modified by applying a water insoluble polymer membrane. The core composition as well as the membrane thickness are varied in order to achieve desired release profiles, from rapid release rate changing to near zero order release profiles with or without a lag time of up to 6 hours. The drug release from the dosage form of the invention is controlled by dual mechanism, viz., the dissolved drug first diffuses through the gelled polymer matrix and then through primarily a water insoluble polymer (semi-permeable) membrane, thereby providing the flexibility of modifying the release profiles including lag time for therapeutic agents for maximizing efficacy and patient compliance. As an illustration of this flexibility, the release profiles of Levalbuterol and Sotalol are described.
PCT/US2001/010175 2000-04-19 2001-03-30 Dual mechanism timed release dosage forms for low dose drugs WO2001080824A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001247887A AU2001247887A1 (en) 2000-04-19 2001-03-30 Dual mechanism timed release dosage forms for low dose drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55233500A 2000-04-19 2000-04-19
US09/552,335 2000-04-19

Publications (2)

Publication Number Publication Date
WO2001080824A2 WO2001080824A2 (en) 2001-11-01
WO2001080824A3 true WO2001080824A3 (en) 2002-02-07

Family

ID=24204903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010175 WO2001080824A2 (en) 2000-04-19 2001-03-30 Dual mechanism timed release dosage forms for low dose drugs

Country Status (2)

Country Link
AU (1) AU2001247887A1 (en)
WO (1) WO2001080824A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
US7250176B1 (en) 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4790597B2 (en) 2003-04-24 2011-10-12 ヤゴテック アーゲー Delayed release tablets with defined core geometry
DE102004043863A1 (en) 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with local and time-controlled drug release in the gastrointestinal tract
US7674479B2 (en) 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
US8703191B2 (en) 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
CN111228229A (en) * 2020-03-31 2020-06-05 鲁南制药集团股份有限公司 Sotalol hydrochloride tablet and preparation process thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4871549A (en) * 1985-07-19 1989-10-03 Fujisawa Pharmaceutical Co., Ltd. Time-controlled explosion systems and processes for preparing the same
US4919938A (en) * 1986-07-09 1990-04-24 Merck Sharp & Dohme Ltd. Sustained release pharmaceutical compositions in oral dosage form
EP0664118A1 (en) * 1991-10-04 1995-07-26 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
EP0793959A1 (en) * 1996-03-07 1997-09-10 Takeda Chemical Industries, Ltd. Controlled-release composition
WO2000050010A1 (en) * 1999-02-26 2000-08-31 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4871549A (en) * 1985-07-19 1989-10-03 Fujisawa Pharmaceutical Co., Ltd. Time-controlled explosion systems and processes for preparing the same
US4919938A (en) * 1986-07-09 1990-04-24 Merck Sharp & Dohme Ltd. Sustained release pharmaceutical compositions in oral dosage form
EP0664118A1 (en) * 1991-10-04 1995-07-26 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
EP0793959A1 (en) * 1996-03-07 1997-09-10 Takeda Chemical Industries, Ltd. Controlled-release composition
WO2000050010A1 (en) * 1999-02-26 2000-08-31 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US9504699B2 (en) 2006-08-03 2016-11-29 Hznp Limited Delayed-release glucocorticoid treatment of rheumatoid disease

Also Published As

Publication number Publication date
WO2001080824A2 (en) 2001-11-01
AU2001247887A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
WO2001080824A3 (en) Dual mechanism timed release dosage forms for low dose drugs
Arora et al. Pulsatile drug delivery systems: An approach for controlled drug delivery
Langer Implantable controlled release systems
ES2272344T3 (en) MULTI-PAPER LAMINAR PREPARATION BASED ON HYDROPHYL POLYMERS FOR QUICK RELEASE OF ACTIVE PRINCIPLES.
EP0266929B1 (en) Stressed polymeric device for controlled release of a substance to an ambient environment
US20220273806A1 (en) Use of fluorine-containing compound-modified cationic polymer as drug carrier and preparation method
AU2014270116B2 (en) Transdermal delivery system
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
EP2827884A1 (en) Silk reservoirs for drug delivery
US20030185882A1 (en) Pharmaceutical compositions containing oxybutynin
JPS62267221A (en) Novel medicine
CN1251987A (en) Dasage forms comprising separate portions of R- and S-enantiomers
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
WO2006130455A3 (en) Bioresorbable polymer matrices and methods of making and using the same
MXPA02006868A (en) Osmotic device within an osmotic device.
JPH10505264A (en) Dry coated tablet with a sharpened area on the core
JP2003509354A5 (en)
Shanmugan et al. Chronotherapeutic drug delivery systems
WO2002098464A3 (en) Liquid polymer composition for prevention and treatment of the oral cavity diseases
NZ211053A (en) Three-layer laminate film device for controlled release of active agent
Patel et al. Pulsatile drug delivery system: a review
JP2590226B2 (en) Dosage form for diltiazem administration
US4751071A (en) Composition comprising salbutamol
EP2566463B1 (en) Extended release thiocolchicoside tablets
CN108338976A (en) A kind of nifedipine double-layer osmotic pump tablet and preparation method thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP